Monday, April 13, 2020

Largest US Study Of COVID-19 Admissions Reveals Single Biggest Factor In Hospitalization

The largest study to date of US hospital admissions for COVID-19 reveals that obesity and age are the largest factors in whether a person had to be admitted to a hospital.
The study, consisting of 4,103 patient records of those who tested positive for the virus between March 1st and April 2nd, revealed that "The chronic condition with the strongest association with critical illness was obesity, with a substantially higher odds ratio than any cardiovascular or pulmonary disease," according to Christopher M. Petrilli of NYU's Grossman School and lead author of the paper "Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York City," printed April 11th on the medRxiv pre-print server, according to ZD.net, which notes that the paper has not undergone peer-review.
Obesity was defined as a body mass index (BMI) of 30 or greater.
Of the 4,103 patients in the study, 1,999 required hospital admission and 650 either required intensive care, mechanical ventilation, were discharged to hospice and/or died.
"We find particularly strong associations of older age, obesity, heart failure and chronic kidney disease with hospitalization risk, with much less influence of race, smoking status, chronic pulmonary disease and other forms of heart disease."
The study is "the largest case series from the United States to date," according to Petrilli and colleagues , who sought to understand "which patients are most at risk for hospitalization is crucial for many reasons."
Writing in The Lancet on March 31st, RNA virus researcher Gregory Poland summed-up the conditions aggravating the COVID-19 situation globally: "We have an increasingly older age demographic across virtually all countries, as well as unprecedented rates of obesity, smoking, diabetes, and heart and lung disease, and an ever-growing population of people who are immunocompromised—all comorbidities that lead to significantly higher risks of severe disease and death from coronavirus disease 2019 (COVID-19)."
And Drs. David S. Ludwig and Richard Malley of Boston Children's Hospital wrote in The New York Times on March 30th that Americans' risk from the virus is compounded by the fact that they are generally "too diseased."
"The huge burden of obesity and other chronic conditions among Americans puts most of us at direct risk," they wrote. "In fact, with obesity rates in the United States much higher than affected countries like South Korea and China, our outcomes — economic- and health-wise — could be much worse." -ZD.net
The authors point out that obesity "is well-recognized to be a pro-inflammatory condition," while COVID-19 triggers an inflammatory immune response.
"Hyperinflammatory states are well described in severe sepsis," they write, "however, the degree to which Covid-19 related inflammation is similar to or different than that typically found in sepsis is unknown." They also note that COVID-19 patients have displayed blood clotting, or "hypercoaguability" which presents as thrombosis or embolisms.
The authors suggest future studies to determine what role inflammation plays, writing "We did not have inflammatory markers available for non-hospitalized patients; it is possible that these would have been strong predictors for hospitalization risk as well if available."
Of note, Chinese researchers studying 577 COVID-19 patients at one hospital found that older patients with inflammation were most likely to die of the disease after 12 days (study here).
In a nutshell, they found that those over 60-years-old with a CRP (C-Reactive protein, an inflammation marker) over 34 mg/L had a 33.2% chance of dying within 12 days of admission to the hospital.
In short, older, obese people with inflammatory conditions appear to be the least likely to survive COVID-19.

Glancy Law - Securities Class Actions

PAYS Class Action Lawsuit Investor Deadline approaches for PaySign, Inc. recovery investment losses

From GlancyLaw.com 4/13/2020

LOS ANGELES, April 02, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 18, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of PaySign, Inc. ("PaySign" or "the Company") (NASDAQ: PAYS) investors who purchased securities between March 12, 2019 and March 15, 2020, inclusive (the “Class Period”).
If you suffered a loss on your PaySign investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information here or contact Charles H. Linehan, of GPM at310-801-2829, via email shareholders@glancylaw.com or visit our website at www.glancylaw.com to learn more about your rights.
On March 16, 2020, PaySign delayed the filing of its annual report for the fiscal year ended December 31, 2019 due to an ongoing audit. The Company also disclosed that “management identified material weaknesses related to (i) assessment of internal controls over financial reporting and (ii) information technology general controls.”
On this news, the Company’s share price fell $0.93, or nearly 17%, to close at $4.59 per share on March 16, 2020, thereby injuring investors. The complaint alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) that PaySign’s internal control over financial reporting was not effective; (2) that PaySign’s information technology general controls were not effective; and (3) as a result, Defendants’ statements about PaySign’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired PaySign securities during the Class Period, you may move the Court no later than May 18, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-801-2829, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-801-2829
shareholders@glancylaw.com
www.glancylaw.com

Data Byte - DataByte-PAYS


Case Data Byte  
Law Firm Glancy Prongay & Murray LLP
Company Name Paysign, Inc.
Stock Symbol PAYS 
Class Period March 12, 2016 and March 15, 2020
Lead Plaintiff Motion Deadline May 18, 2020
Contact Attorney Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067
Contact Phone 310-801-2829
Contact Email shareholders@glancylaw.com
Press Release https://www.glancylaw.com/news-faqs/pays-class-action-lawsuit-investor-deadline-approaches-for-paysign-inc-recovery-investment-losses/
Case Summary On March 16, 2020, PaySign delayed the filing of its annual report for the fiscal year ended December 31, 2019 due to an ongoing audit. The Company also disclosed that “management identified material weaknesses related to (i) assessment of internal controls over financial reporting and (ii) information technology general controls.”
 
About the Company PaySign, Inc. provides prepaid card programs and processing services under the PaySign brand to corporations, government agencies, universities, and other organizations. The company offers various services, including transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary card-processing platform. It also develops prepaid card products for healthcare reimbursement payments, pharmaceutical assistance, donor compensation, corporate and incentive rewards, and expense reimbursement cards; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, the company offers Buy and Bill programs for patients to purchase directly from physician's office or through an infusion center for physician administered therapies; payment solution for source plasma collection centers; and PaySign Premier, a demand deposit account debit card, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and internationally. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. was incorporated in 1995 and is based in Henderson, Nevada.
 
 
   
Yahoo Finance https://finance.yahoo.com/quote/PAYS/
Website https://www.paysign.com/
Wikipedia none
Join Action Link https://www.glancylaw.com/cases-application/join-case/paysign-inc/

Thursday, April 9, 2020

A Breakdown on Current Testing Procedures



RTIX Class Action Deadline Looms

Vital videos about the COVID-19 COVERT 19 scam

Physician utterly demolishes the 'covid-19' test' and the very existence of the 'virus' - an absolutely must-watch




 

Dr. Thomas Cowan - Covid19 Fails Koch's Postulates




 

New York doctor - it's NOT 'COVID-19' - people are dying through lack of oxygen (5G STOPS PEOPLE ABSORBING OXYGEN)



5G, 60 GHz, Oxygen Absorption, You, and Coronavirus


Read more - https://ourgreaterdestiny.org/2020/02/5g-60-ghz-oxygen-absorption-you-and-coronavirus/

 

Retired President Of Microsoft Canada, Frank Clegg 5G Wireless IS NOT SAFE




 

German journalist goes to hospital 'teeming with coronavirus patients' - how can doctors cope? - and finds NO ONE THERE




"No Way Back" - 20yr FEMA Officer Lays Out The VERY Long Planned "GREAT RESET" Agenda



George Soros-Funded Group to Governors: Release as Many Prisoners as Possible Due to Coronavirus

From David Icke.com

'The Brennan Center for Justice, which is heavily financed by George Soros, has submitted a letter to the governors of all fifty states urging them to use executive action to “release as many people as possible from incarceration” due to coronavirus fears “provided they do not pose serious public safety threats.”

The letter cited concern that the U.S. prison population could face greater risk of illness and death than the general public due to the Chinese coronavirus pandemic.

The Brennan Center recommended that all governors use the power of clemency where they can.

The document states:
Ideally, people who are older, medically compromised, or nearing the end of their prison terms could have their sentences commuted to time served and be released outright. We urge you to grant the broadest relief to the largest group of people possible, but should this prove impracticable, we urge you to consider clemency relief in other forms, such as reprieves, which temporarily suspend a sentence, or conditional pardons.

The Brennan Center cited its own research to claim that extending clemency to “especially vulnerable” prisoners “will not jeopardize public safety.”

It claimed:
Our own research has shown that state prison sentences are often too long to begin with, and that roughly 14 percent of imprisoned people have “served sufficiently long prison terms and could likely be released within the next year with little risk to public safety.”

Moreover, researchers have shown, time and time again, that the likelihood of recidivism plummets as people age. One seminal study by the U.S. Sentencing Commission found that “offenders over sixty years old at the time of release had a recidivism rate of 16.0 percent” —roughly a quarter the rate of people released before age 21.'

RTIX Deadline approaching in the Class Action Lawsuit Against of RTI Surgical Holdings, Inc. for investors who suffered losses

From GlancyLaw.com

LOS ANGELES, April 08, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of RTI Surgical Holdings, Inc. (“RTI Surgical” or “the Company”) (NASDAQ: RTIX) investors who purchased securities between March 7, 2016 and March 16, 2020, inclusive (the “Class Period”).
If you suffered a loss on your RTI Surgical investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can join the action here, or contact Charles H. Linehan, of GPM at 310-957-9549, Toll-Free at 888-773-9224, via email shareholders@glancylaw.com or visit our website at www.glancylaw.com to learn more about your rights.  
On March 16, 2020, after the market closed, RTI Surgical disclosed that its Audit Committee was investigating “the Company’s revenue recognition practices regarding the timing of revenue with respect to certain contractual arrangements, primarily with OEM customers, including the accounting treatment, financial reporting and internal controls related to such arrangements.” According to RTI Surgical, the investigation was “precipitated by an ongoing SEC investigation related to the periods 2014 through 2016.”
On this news, the Company’s share price fell $0.40, or over 14%, to close at $2.35 per share on March 17, 2020, thereby injuring investors.
The complaint alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) that the Company inappropriately recognized revenues with respect to certain contractual arrangements, including other equipment manufacturer customers; (2) that the Company’s internal controls over financial reporting were not effective; (3) that as a result, the Company would be forced to delay the filing of its Form 10-K; (4) as a result of the foregoing, RTI Surgical’s public statements were materially false and misleading at all relevant times.  Follow us for updates on LinkedInTwitter, or Facebook.
If you purchased RTI Surgical securities during the Class Period, you may move the Court no later than May 22, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-801-2829, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.  Click here to join the RTIX class action.
This article may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-801-2829
shareholders@glancylaw.com
www.glancylaw.com

Data Byte DataByte-RTIX2

Case Data Byte 
Law FirmGlancy Prongay & Murray LLP
Company NameRTI Surgical
Stock SymbolRTIX
Class PeriodMarch 7, 2016 and March 16, 2020
Lead Plaintiff Motion DeadlineMay 22, 2020
Contact AttorneyCharles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067
Contact Phone310-801-2829
Contact Emailshareholders@glancylaw.com
Press Releasehttps://www.glancylaw.com/news-faqs/rtix-deadline-approaching-in-the-class-action-lawsuit-against-of-rti-surgical-holdings-inc-for-investors-who-suffered-losses/ 
Case SummaryOn March 16, 2020, after the market closed, RTI Surgical disclosed that its Audit Committee was investigating “the Company’s revenue recognition practices regarding the timing of revenue with respect to certain contractual arrangements, primarily with OEM customers, including the accounting treatment, financial reporting and internal controls related to such arrangements.” According to RTI Surgical, the investigation was “precipitated by an ongoing SEC investigation related to the periods 2014 through 2016.”
 
About the CompanyThe company was founded by Matthew Songer, and its first major product was the Songer Cable, used in spine surgeries. The Songer Cable was featured in the book, Contemporary Management of Spinal Cord Injuries.[1] Pioneer Surgical later developed products in the spine, biologics, orthopedics, and cardio-thoracic markets. Michigan Governor Jennifer Granholm visited Pioneer in 2005 and cited Pioneer as an example of job creation in the Upper Peninsula.[2] In 2007, Pioneer acquired Angstrom Medica, a Massachusetts-based medical company focused on nanotechnology[3] and Encelle, A North Carolina-based company researching and developing tissue regeneration products.[4] Pioneer was acquired in July 2013 by RTI Biologics, and the firm was then renamed RTI (“ready to implant”) Surgical.
 
 
  
Yahoo Financehttps://finance.yahoo.com/quote/rtix
Websitehttp://www.rtix.com/en_us/
Wikipediahttps://en.wikipedia.org/wiki/RTI_Surgical

Dr. Fauci Says US COVID-19 US Deaths Could Be As Low As 60K After Warning "Millions Could Die"

From Zero Hedge:
A few weeks ago, Dr. Anthony Fauci sat down in front of Congress and warned that millions of Americans could die if the federal government didn't take the outbreak seriously.
And now, after the Trump Administration scrambled to ramp up testing capacity and the states worked with the Feds, private entities, and others (including in some cases foreign nations) to distribute ventilators as Gov. Andrew Cuomo painted a horrifying portrait of sickened New Yorkers suffocating to death in hospital hallways because there were no ventilators available.
Well, yesterday, NYC Mayor de Blasio said that, after a few days of near capacity numbers, hospitalizations have dropped by such a steep degree that the city believes it has enough ventilators on hand, and won't need any more.
Now on Thursday, Dr. Fauci is taking to cable news to spread the message of optimism that has lifted US stocks over the past few days: Instead of the 240k figure used by President Trump as recently as two weeks ago, Dr. Fauci told NBC News that if the public continued to stick to the "mitigation efforts", that the death toll might be as low as 60k.
To be sure, while lockdown conditions are in place around the world, there are still a dozen or so states who don't have mandatory closure or curfew orders in place.
Watch @savannahguthrie’s full interview with Dr. Anthony Fauci, who talks about efforts to control the spread of coronavirus, and how much longer social distancing will last.
61 people are talking about this
Dr. Fauci, director of the National Institute of Allergy and Infectious Diseases, said he’s "cautiously optimistic" that the US might soon see cases reach the back-side of the curve as the "turnaround and that curve not only flatten, but are coming down.” He made clear, however, that the virus is never going to disappear, and things will still be different even after we've finished going "back to normal".
"When we attempt to get back to normal, we have to have in place the ability, when it starts to try and rear its ugly head, we can absolutely suppress it by identification, isolation, contact tracing,” he said.
He also warned that this outbreak is a "wake up call", warning that more serious outbreaks might occur in the future.
"When you're talking about getting back to normal, we know now that we can get hit by a catastrophic outbreak like this,” he said. “It can happen again, so we really need to be prepared to respond in a much more vigorous way.”
Additionally, during an interview with CBS News (the good doctor routinely makes at least 2-3 appearances on cable news a day, an extremely rigorous media schedule in light of his many responsibilities), Dr. Fauci warned that Americans might be able to take their summer vacations if we continue sticking to the "mitigation strategies", and prevent a full-one "resurgence" of the virus, he said on "CBS This Morning".
"It can be in the cards," he said.
But, Dr. Fauci warned, "and I say that with some caution, because as I said, when we do that, when we pull back and try to open up the country, as we often use that terminology, we have to be prepared that when the infections start to rear their heads again that we have it in place a very aggressive and effective way to identify, isolate, contract trace and make sure we don't have those spikes we have now. So the answer to your question is yes, if we do the things that we need to do to prevent the resurgence."
Getting back to normal is not like a light switch that you turn on and off, Fauci said, adding it’ll be gradual and depend on where in the country you live.
"The bottom line of it all is, that what we see looking forward, it is very likely that we will progress towards the steps towards normalization as we get to the end of this thirty days. And I think that’s going to be a good time to look and see how quickly can we make that move to try and normalize. But hopefully, and hopefully, by the time we get to the summer we will have taken many steps in that direction," he added.

Asked if he would be taking a vacation, Fauci smiled and laughed: “I don’t take vacations," he replied.


AOSL Class Action Claims



NYC Doctor: We're Treating 'Wrong Disease' With COVID-19 Patients

From Newsmax:

A New York City critical care doctor is raising doubts about the treatment prescribed for COVID-19 patients.
In a YouTube video posted March 31, Dr. Cameron Kyle-Sidell questioned whether the virus was actually causing Acute Respiratory Distress Syndrome.
“This is the disease that every hospital is preparing to treat,” he said. “And this is the disease for which in the next two to six weeks, 100,000 Americans might be put on a ventilator.”
But he said the things he is seeing just don’t add up.
“The patients I’m seeing in front of me, the lungs I’m trying to improve have led me to believe COVID-19 is not this disease,” he said.
“In short, I believe we are treating the wrong disease.
“I feel compelled to get this information out. COVID-19 lung disease, as far as I can see, is not a pneumonia and should not be treated as one. Rather, it appears that it is some kind of viral-induced disease, most resembling high altitude sickness.
“It’s as if tens of thousands of my fellow New Yorkers are on a plane at 30,000 feet and cabin pressure is slowly being let out. These patients are slowly being starved of oxygen.”
Kyle-Sidell conceded he does not know the final answer to treating the disease, “but I’m quite sure a ventilator is not it.”
“That’s not to say we don’t need ventilators,” he said. “We absolutely need them. They’re the only way at this time we are able to give a little more oxygen to patients who need it.”


Wednesday, April 8, 2020

It’s now clear that Fauci is trying to DEPRIVE America of a coronavirus cure


Image: It’s now clear that Fauci is trying to DEPRIVE America of a coronavirus cure


(Natural News) Wuhan coronavirus (COVID-19) task force head Dr. Anthony Fauci doesn’t want Americans taking hydroxychloroquine, or chloroquine, to treat the virus, and many people are wondering why not?
One of them is White House economic advisor Peter Navarro, who reportedly exploded at Fauci the other day for trying to downplay the benefits of this extremely inexpensive generic drug for malaria, while emphasizing the alleged superiority of some future vaccine for the Wuhan coronavirus (COVID-19) that doesn’t even exist yet.
Even though hydroxychloroquine is shaping up to be the most effective weapon in the arsenal – at least from a pharmaceutical perspective – for treating this coronavirus, Fauci isn’t having any of it. And that’s because, as he’s now proven, he works for Big Vaccine and not for the American people.
During a recent roundtable, which was reportedly attended by Wuhan coronvirus (COVID-19) response coordinator Deborah Birx, Jared Kushner, acting Homeland Security Secretary Chad Wolf, and Food and Drug Administration (FDA) acting commissioner Stephen Hahn, Navarro passed out folders containing data on the benefits of hydroxychloroquine.
According to Navarro and what he passed out, the studies he’s seen, mostly from overseas, show that this malaria drug shows “clear therapeutic efficacy” against the Wuhan coronavirus (COVID-19), and it can be procured for just pennies per dose.
Almost immediately, Fauci began pushing back against Navarro’s claims, stating that “there’s only anecdotal evidence” that hydroxychloroquine works against COVID-19. This “just set Peter off,” according to one of the others who was present, prompting Navarro to explain that “science, not anecdote” shows that hydroxychloroquine does, in fact, work against the Wuhan coronavirus (COVID-19).
Listen below to The Health Ranger Report as Mike Adams, the Health Ranger, talks to Dr. Eduard Fatakhov about how to beat the coronavirus through nutrition:

Navarro also called out Fauci for opposing Trump’s early travel restrictions

In his heated rant against Fauci’s nonsense, Navarro went on to chastise Fauci for being one of the earliest voices to oppose President Donald Trump’s early travel restrictions with China, emphasizing that Fauci had claimed that “travel restrictions don’t work.”
The group ended up agreeing that the best path forward is to get the drug to the “hot zones” because it does help, and to allow patients to make the decision whether or not to use hydroxychloroquine themselves with the guidance of their physicians.
During a recent press conference, President Trump also indicated that he had ordered 29 million doses of hydroxychloroquine to be placed into the Strategic National Stockpile.
“There has never been a confrontation in the task force meetings like the one yesterday,” claimed a source about Navarro’s outburst at Fauci. “People speak up and there’s robust debate, but there’s never been a confrontation. Yesterday was the first confrontation.”
When polled about the effectiveness of hydroxychloroquine, about 37 percent of some 6,227 doctors in 30 countries indicated that it is currently the “most effective therapy” that they have at their disposal. This is compared to at least 14 other potential treatment options that are currently available.
A whopping 72 percent of COVID-19 cases in Spain have had hydroxychloroquine prescribed, while almost half of all cases in Italy have had the drug prescribed. Hydroxychloroquine is also being used in about 41 percent of Wuhan coronavirus (COVID-19) cases in Brazil, 39 percent of cases in Mexico, 28 percent of cases in France, and 23 percent of cases in the United States.
Overall, almost 20 percent of physicians are now prescribing hydroxychloroquine for their high-risk patients, while a mere eight percent are prescribing it for their low-risk patients.
To keep up with the latest news about the Wuhan coronavirus (COVID-19), be sure to check out Pandemic.news.